γδ T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes

Journal of Immunology

Volumn 184, Issue 1, 2010, Pages 134-140

  Braza, Mounia Sabrina ^a   Caraux, Anouk ^a   Rousset, Thérèse ^a   De Micheaux, Sylvie Lafaye ^c   Sicard, Hélène ^c   Squiban, Patrick ^c   Costes, Valérie ^a,b   Klein, Bernard ^a,b   Rossi, Jean François ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c INNATE PHARMA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 2; INTERLEUKIN 33; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; CCR7 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR DISTRIBUTION; CHILD; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; LYMPH NODE; LYMPH VESSEL; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; BIOSYNTHESIS; BLOOD; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL19; CHEMOKINE CCL21; CHEMOKINE CXCL12; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, CCR7; RECEPTORS, CXCR4; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 73949115833     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901980     Document Type: Article

References (45)

1. Yunis, J. J., M. M. Oken, M. E. Kaplan, K. M. Ensrud, R. R. Howe, and A. Theologides. 1982. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N. Engl. J. Med. 307: 1231-1236.
2. Craxton, A., D. Magaletti, E. J. Ryan, and E. A. Clark. 2003. Macrophage- and dendritic cell - dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101: 4464-4471.
3. Dave, S. S., G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, et al. 2004. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351: 2159-2169.
4. Staudt, L. M., and S. Dave. 2005. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol. 87: 163-208.
5. Yu, P., and Y. X. Fu. 2006. Tumor-infiltrating T lymphocytes: friends or foes? Lab. Invest. 86: 231-245.
6. Bendelac, A., M. Bonneville, and J. F. Kearney. 2001. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1: 177-186.
7. Bonneville, M. 2001. γ δ Lymphocytes. Encyclopedia of life Sciences (Nature Publishing Group):1-7.
8. De Rosa, S. C., J. P. Andrus, S. P. Perfetto, J. J. Mantovani, L. A. Herzenberg, L. A. Herzenberg, and M. Roederer. 2004. Ontogeny of γδ T cells in humans. J. Immunol. 172: 1637-1645.
9. Hayday, A. C. 2000. γδ cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18: 975-1026.
10. Burjanadzé, M., M. Condomines, T. Reme, P. Quittet, P. Latry, C. Lugagne, F. Romagne, Y. Morel, J. F. Rossi, B. Klein, and Z. Y. Lu. 2007. In vitro expansion of γδ T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br. J. Haematol. 139: 206-216.
11. Sicard, H., T. Al Saati, G. Delsol, and J. J. Fournié. 2001. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol. Med. 7: 711-722.
12. Thompson, K., J. Rojas-Navea, and M. J. Rogers. 2006. Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 107: 651-654.
13. Espinosa, E., C. Belmant, F. Pont, B. Luciani, R. Poupot, F. Romagné, H. Brailly, M. Bonneville, and J. J. Fournié. 2001. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J. Biol. Chem. 276: 18337-18344.
14. Corvaisier, M., A. Moreau-Aubry, E. Diez, J. Bennouna, J. F. Mosnier, E. Scotet, M. Bonneville, and F. Jotereau. 2005. Vγ9Vδ2 T cell response to colon carcinoma cells. J. Immunol. 175: 5481-5488. (Pubitemid 41456435)
15. Viey, E., G. Fromont, B. Escudier, Y. Morel, S. Da Rocha, S. Chouaib, and A. Caignard. 2005. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174: 1338-1347.
16. Sicard, H., S. Ingoure, B. Luciani, C. Serraz, J. J. Fournié, M. Bonneville, J. Tiollier, and F. Romagné. 2005. In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175: 5471-5480.
17. Fisch, P., A. Moris, H. G. Rammensee, and R. Handgretinger. 2000. Inhibitory MHC class I receptors on γδ T cells in tumour immunity and autoimmunity. Immunol. Today 21: 187-191. (Pubitemid 30184789)
18. Glatzel, A., D. Wesch, F. Schiemann, E. Brandt, O. Janssen, and D. Kabelitz. 2002. Patterns of chemokine receptor expression on peripheral blood γδ T lymphocytes: strong expression of CCR5 is a selective feature of Vd2/Vγ9γδ T cells. J. Immunol. 168: 4920-4929. (Pubitemid 34498305)
19. Poccia, F., B. Cipriani, S. Vendetti, V. Colizzi, Y. Poquet, L. Battistini, M. López- Botet, J. J. Fournié, and M. L. Gougeon. 1997. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive VγVδ2 T lymphocytes. J. Immunol. 159: 6009-6017.
20. Kim, C. H., D. J. Campbell, and E. C. Butcher. 2001. Nonpolarized memory T cells. Trends Immunol. 22: 527-530.
21. Luther, S. A., and J. G. Cyster. 2001. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2: 102-107.
22. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. Nat. Immunol. 2: 123-128.
23. + T cells: follicular homing takes center stage in T helper cell responses. Trends Immunol. 23: 250-254.
24. Kaplan, A. P. 2001. Chemokines, chemokine receptors and allergy. Int. Arch. Allergy Immunol. 124: 423-431.
25. Müller, G., U. E. Höpken, H. Stein, and M. Lipp. 2002. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J. Leukoc. Biol. 72: 1-8.
26. Ngo, V. N., H. L. Tang, and J. G. Cyster. 1998. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J. Exp. Med. 188: 181-191.
27. Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127. (Pubitemid 30398626)
28. Yoshida, R., T. Imai, K. Hieshima, J. Kusuda, M. Baba, M. Kitaura, M. Nishimura, M. Kakizaki, H. Nomiyama, and O. Yoshie. 1997. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J. Biol. Chem. 272: 13803-13809.
29. Corcione, A., L. Ottonello, G. Tortolina, P. Facchetti, I. Airoldi, R. Guglielmino, P. Dadati, M. Truini, S. Sozzani, F. Dallegri, and V. Pistoia. 2000. Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J. Natl. Cancer Inst. 92: 628-635.
30. Csanaky, G. 1994. High endothelial venules and cell adhesion molecules in B cell chronic lymphocytic leukaemia and related low grade B-cell lymphoma/- leukaemia. I. High endothelial venules and lymphocyte migration. Histol. Histopathol. 9: 571-575.
31. Harris, N. L., E. S. Jaffe, H. Stein, P. M. Banks, J. K. Chan, M. L. Cleary, G. Delsol, C. De Wolf-Peeters, B. Falini, K. C. Gatter, et al. 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392.
32. Kunzmann, V., E. Bauer, J. Feurle, F. Weissinger, H. P. Tony, and M. Wilhelm. 2000. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392. (Pubitemid 30463353)
33. Inman, B. A., X. Frigola, K. J. Harris, S. M. Kuntz, C. M. Lohse, B. C. Leibovich, and E. D. Kwon. 2008. Questionable relevance of γ δ T lymphocytes in renal cell carcinoma. J. Immunol. 180: 3578-3584.
34. Kobayashi, H., Y. Tanaka, J. Yagi, H. Toma, and T. Uchiyama. 2001. γ/δ T cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. 50: 115-124.
35. Farcet, J. P., P. Gaulard, J. P. Marolleau, J. P. Le Couedic, T. Henni, M. F. Gourdin, M. Divine, C. Haioun, S. Zafrani, M. Goossens, et al. 1990. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor γδ. Blood 75: 2213-2219.
36. Baekkevold, E. S., T. Yamanaka, R. T. Palframan, H. S. Carlsen, F. P. Reinholt, U. H. von Andrian, P. Brandtzaeg, and G. Haraldsen. 2001. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J. Exp. Med. 193: 1105-1112.
37. Carlsen, H. S., G. Haraldsen, P. Brandtzaeg, and E. S. Baekkevold. 2005. Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules. Blood 106: 444-446.
38. Amé-Thomas, P., H. Maby-El Hajjami, C. Monvoisin, R. Jean, D. Monnier, S. Caulet-Maugendre, T. Guillaudeux, T. Lamy, T. Fest, and K. Tarte. 2007. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 109: 693-702.
39. Vega, F., L. J. Medeiros, W. H. Lang, A. Mansoor, C. Bueso-Ramos, and D. Jones. 2002. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. Br. J. Haematol. 117: 569-576.
40. Tarte, K., and B. Klein. 1999. Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13: 653-663. (Pubitemid 29243614)
41. Viey, E., C. Lucas, F. Romagne, B. Escudier, S. Chouaib, and A. Caignard. 2008. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J. Immunother. 31: 313-323.
42. Bennouna, J., E. Bompas, E. M. Neidhardt, F. Rolland, I. Philip, C. Galéa, S. Salot, S. Saiagh, M. Audrain, M. Rimbert, et al. 2008. Phase-I study of Innacell γδ, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57: 1599-1609.
43. Laurent, G., J. F. Rossi, E. W. Van Den Neste, F. Audibert, H. Ghesquieres, S. Le Gouill, P. Feugier, H. Sicard, S. Ingoure, E. Soule, and S. L. de Micheaux. 2008. A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vγ9Vδ2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data. ASH Annual Meeting Abstracts 112: 1002.
44. 18F]fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leuk. Lymphoma 48: 381-388.
45. de Vries, I. J., W. J. Lesterhuis, J. O. Barentsz, P. Verdijk, J. H. van Krieken, O. C. Boerman, W. J. Oyen, J. J. Bonenkamp, J. B. Boezeman, G. J. Adema, et al. 2005. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23: 1407-1413.